A phase IIa trial of the new tuberculosis vaccine, MVA85A, in HIV- and/or Mycobacterium tuberculosis-infected adults.

RATIONALE: Novel tuberculosis (TB) vaccines should be safe and effective in populations infected with Mycobacterium tuberculosis (M.tb) and/or HIV for effective TB control. OBJECTIVE: To determine the safety and immunogenicity of MVA85A, a novel TB vaccine, among M.tb- and/or HIV-infected persons in...

Full description

Bibliographic Details
Main Authors:	Scriba, T, Tameris, M, Smit, E, van der Merwe, L, Hughes, E, Kadira, B, Mauff, K, Moyo, S, Brittain, N, Lawrie, A, Mulenga, H, de Kock, M, Makhethe, L, Janse van Rensburg, E, Gelderbloem, S, Veldsman, A, Hatherill, M, Geldenhuys, H, Hill, A, Hawkridge, A, Hussey, G, Hanekom, W, McShane, H, Mahomed, H
Format:	Journal article
Language:	English
Published:	2012

A phase IIa trial of the new tuberculosis vaccine, MVA85A, in HIV- and/or Mycobacterium tuberculosis-infected adults.

Similar Items